ArticleFrontiers in cardiovascular medicine2026
Yiqihuoxue formula improves atherosclerosis by regulating macrophage polarization associated with enhanced STAT6/PPARγ pathway.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerosis (AS) is a major contributor to deaths from cardiovascular diseases. Yiqihuoxue Formula (YQHXF) reflects the traditional Chinese medicine principle of "Qi-invigorating and blood-activating." This study investigates the anti-atherosclerotic effects and mechanism of YQHXF through the signal transducer and activator of transcription 6 (STAT6)/ peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathway and macrophage polarization. Methods: Ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) was used to detect the components of YQHXF-containing serum (YQHXF-CS). Using oxidized low-density lipoprotein (ox-LDL), RAW264.7 macrophages were induced into foam cells Results: The results showed that YQHXF-CS contained 2,317 components. Conclusions: YQHXF ameliorates AS, as evidenced by reduced foam cell formation, alleviated vascular lesions, and promotion of anti-inflammatory M2 macrophage polarization; these effects were associated with enhanced STAT6/PPARγ signaling. This validates the theory of "Qi-invigorating and blood-activating" and highlights YQHXF's therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.